MedImmune

PhRMA elects new members of board of directors

Monday, June 22, 2015 12:26 PM

The Pharmaceutical Research and Manufacturers of America (PhRMA) has announced the election of five of its newest members to its board of directors.

More... »


AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden

Wednesday, May 20, 2015 03:18 PM

AstraZeneca plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics. The new facility will supply medicines for clinical trial programs of AZ and MedImmune, the company's global biologics R&D arm, from the end of 2018, and will deliver finished products for commercial use once fully operational by 2019.

More... »


AstraZeneca, Celgene collaborate on serious blood cancers

Friday, May 1, 2015 12:51 PM

AstraZeneca and MedImmune, AZ’s global biologics R&D arm, have entered into an exclusive collaboration agreement with Celgene for the development and commercialization of MEDI4736 across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma.

More... »

Immunocore, MedImmune collaborate on immuno-oncology combination trials

Friday, April 17, 2015 12:36 PM

Immunocore, a biotechnology company developing novel biological drugs to treat cancer and other diseases headquartered outside Oxford, England, and MedImmune, the global biologics R&D arm of AstraZeneca, have entered into a second collaboration.

More... »

DARPA awards Inovio $45M Ebola program grant

Thursday, April 9, 2015 01:43 PM

Inovio Pharmaceuticals, based in Plymouth Meeting, Pa., has been awarded a $45 million grant from the Defense Advanced Research Projects Agency (DARPA) to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola.

More... »

MedImmune, Joslin Diabetes Center collaborate on metabolic disease research

Wednesday, March 11, 2015 12:21 PM

MedImmune, the global biologics R&D arm of AstraZeneca, and Joslin Diabetes Center, a diabetes research and clinical care organization based in Boston, Mass., have inked a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity and related metabolic disorders.

More... »

MedImmune, NIST partner to advance development of biological therapies

Monday, February 23, 2015 01:06 PM

MedImmune, the global biologics R&D arm of AstraZeneca, and the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) have signed a five-year agreement to jointly support research that will help advance drug discovery and manufacturing. The effort will focus on tools and measurements that will be used in the development and production of biopharmaceuticals, which are drugs and treatments derived from biological, rather than chemical, sources.

More... »

COMBACTE-MAGNET launched to revitalize antibiotic development

Wednesday, February 4, 2015 01:41 PM

Thirty-three European academic partners and five pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the Innovative Medicines Initiative (IMI) antimicrobial resistance research program New Drugs 4 Bad Bugs (ND4BB).

More... »

Inovio appoints Mark Gelder vice president, clinical development

Thursday, January 29, 2015 01:09 PM

Inovio Pharmaceuticals has appointed Mark Stephen Gelder, M.D., as vice president, clinical development. Gelder will be responsible for planning and executing Inovio's clinical development strategy for its immunotherapies against human papillomavirus (HPV)-caused cervical cancer and dysplasia. He will report to Dr. Mark Bagarazzi, Inovio's chief medical officer.

More... »

Tetragenetics, MedImmune collaborate on ion channel drug discovery program

Thursday, January 8, 2015 01:03 PM

Tetragenetics, an emerging biotechnology company based in Cambridge, Mass., will collaborate with MedImmune, the global biologics R&D arm of AstraZeneca, on antibody drug discovery research. Specifically, Tetragenetics will use its proprietary ion channel production technology, SionX, to produce up to five ion channel antigens for MedImmune's antibody drug discovery programs.

More... »


CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs